Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19
Phase 2
Completed
- Conditions
- Coronavirus InfectionCovid-19SARS-CoV-2
- Interventions
- Drug: Ensifentrine Dose 1Drug: Placebo pMDI
- First Posted Date
- 2020-08-26
- Last Posted Date
- 2022-09-22
- Lead Sponsor
- Verona Pharma Inc
- Target Recruit Count
- 45
- Registration Number
- NCT04527471
- Locations
- 🇺🇸
The University of Alabama at Birmingham, Birmingham, Alabama, United States
© Copyright 2025. All Rights Reserved by MedPath